Syndax Pharmaceuticals (NASDAQ: SNDX) announced four abstracts related to its cancer drug Revuforj have been accepted for presentation at the American Society of Clinical Oncology Annual Meeting scheduled for May 29 through June 2, 2026, in Chicago.

The presentations will include an oral presentation featuring data from 21 adults and children with specific types of acute leukemia who received revumenib following hematopoietic stem cell transplantation. The data will cover overall survival rates and relapse rates, with comparisons to a historical patient cohort treated before revumenib became available.

A poster presentation will examine the pharmacokinetic profile of revumenib, focusing on its ability to be administered with gastric acid reducing agents without reduced efficacy, proper dosing adjustments when used with strong CYP3A4 inhibitors, and administration with low-fat meals.

Two additional poster presentations will outline the design of ongoing phase 3 trials testing revumenib in combination with chemotherapy for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

"Our strong presence at ASCO highlights our scientific leadership in menin inhibition and our deep commitment to advancing cancer care," said Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax, according to the company's press release.

Revuforj is an FDA-approved oral menin inhibitor for treating relapsed or refractory acute leukemia with specific genetic markers in patients one year and older. The drug received FDA approval for treating acute leukemia with KMT2A gene translocations and acute myeloid leukemia with NPM1 mutations in patients with limited treatment alternatives.